The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with
aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a …

Long noncoding RNAs (lncRNAs) represent an attractive class of candidates to mediate
cancer risk. Through integrative analysis of the lncRNA transcriptome with genomic data and …

Abstract Prostate cancer antigen 3 (PCA3) is a prostate-specific long noncoding RNA
(lncRNA) involved in the control of prostate cancer (PCa) cell survival, through modulating …

Castration-resistant prostate cancers (CRPC) that arise after the failure of androgen-
blocking therapies cause most of the deaths from prostate cancer, intensifying the need to …

Long noncoding RNAs (lncRNA) have recently been associated with the development and
progression of a variety of human cancers. However, to date, the interplay between known …

Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the
potential to serve as novel markers of disease and to reveal uncharacterized aspects of …

Prostate cancer is one of the most frequently diagnosed malignancies in developed
countries and approximately 248,530 new cases of prostate cancer are likely to be …

Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs
(lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We …

Recent genome‐wide association studies reported strong and reproducible associations of
multiple genetic variants in a large “gene‐desert” region of chromosome 8q24 with …

In PTEN-deficient prostate cancers, AKT signaling may be activated upon suppression of
androgen receptor signaling. Activation of AKT as well as NF-κB signaling involves a key …